We quantified genome-wide patterns of lysine H3K27 acetylation (H3K27ac) in entorhinal cortex samples from Alzheimer's disease (AD) cases and matched controls using chromatin immunoprecipitation and highly parallel sequencing. We observed widespread acetylomic variation associated with AD neuropathology, identifying 4,162 differential peaks (false discovery rate < 0.05) between AD cases and controls. Differentially acetylated peaks were enriched in disease-related biological pathways and included regions annotated to genes involved in the progression of amyloid-β and tau pathology (for example, APP, PSEN1, PSEN2, and MAPT), as well as regions containing variants associated with sporadic late-onset AD. Partitioned heritability analysis highlighted a highly significant enrichment of AD risk variants in entorhinal cortex H3K27ac peak regions. AD-associated variable H3K27ac was associated with transcriptional variation at proximal genes including CR1, GPR22, KMO, PIM3, PSEN1, and RGCC. In addition to identifying molecular pathways associated with AD neuropathology, we present a framework for genome-wide studies of histone modifications in complex disease. 
A lzheimer's disease is a chronic neurodegenerative disorder characterized by cognitive decline and memory loss that contributes substantially to the global burden of disease, affecting in excess of 26 million people worldwide 1 . The symptoms of AD are associated with progressive neuropathology in the neocortex, with regions surrounding the entorhinal cortex being particularly affected early in the disease 2 . These neuropathological hallmarks of AD include the extracellular deposition of neurotoxic amyloid-β (Aβ ) in the form of amyloid plaques and an accumulation of intracellular neurofibrillary tangles composed of hyperphosphorylated tau 3 . Despite progress in understanding risk factors contributing to AD progression, the mechanisms involved in disease progression are not fully understood, and long-term treatments that reverse the cellular disease process in the cortex remain elusive.
There has been considerable success in identifying genetic risk factors for AD 4 . While autosomal dominant mutations in three genes (APP, PSEN1, and PSEN2) can explain early-onset (< 65 years) familial AD, these account for only 1-5% of the total disease burden 5 . Most cases of AD are late-onset (> 65 years), non-Mendelian, and highly sporadic, with susceptibility attributed to the action of highly prevalent genetic variants of low penetrance. In addition to the well-established risk associated with the APOE locus 6 there has been notable success in identifying novel AD-associated variants capitalizing on the power of genome-wide association studies (GWAS) in large sample cohorts; a recent large GWAS meta-analysis of AD, incorporating > 74,000 samples, identified 19 genome-wide significant risk loci for sporadic AD 7 . Despite these advances, little is known about the functional mechanisms by which risk variants mediate disease susceptibility.
Increased understanding about the functional complexity of the genome has led to growing recognition about the likely role of nonsequence-based regulatory variation in health and disease. Building on the hypothesis that epigenomic dysregulation is important in the etiology and progression of AD neuropathology 8 , we and others recently performed the first genome-scale cross-tissue analyses of DNA methylation in AD, identifying robust DNA-methylation differences associated with AD neuropathology across multiple independent human postmortem brain cohorts 9, 10 . To date, however, no study has systematically examined other types of regulatory genomic modifications in AD. In this study, we focus on lysine H3K27 acetylation (H3K27ac), a robust mark of active enhancers and promoters that is strongly correlated with gene expression and transcription-factor binding 11 . Notably, histone deacetylase inhibitors have been shown to ameliorate symptoms of cognitive decline and synaptic dysfunction in mouse models of AD 12 and are promising targets for novel human AD treatments 13 . Despite this, investigations into global levels of histone acetylation in AD have thus far been inconclusive [14] [15] [16] , and no study has taken a genome-wide approach. In fact, few studies have systematically profiled H3K27ac across large numbers of samples in the context of complex disease, and optimal methods for these analyses are still being developed 17 .
Here we used chromatin immunoprecipitation combined with highly parallel sequencing (ChIP-seq) to quantify levels of H3K27ac across the genome in postmortem entorhinal cortex samples from , percentage of hypoacetylated peaks: 65%, 95% CI: 63-66%; Fig. 1 ). Because there are global differences in H3K27ac between males and females-the first principal component of variable H3K27ac was associated with sex in our data ( Supplementary Fig. 6 )-we undertook subsequent sensitivity analyses, confirming that 4,157 (99.9%) of the 4,162 differentially acetylated peaks remained significantly differentially acetylated (FDR < 0.05) when additionally controlling for sex, with showing the raw -log 10 (P) values for differential H3K27ac against chromosomal location from the EdgeR quasi-likelihood F test (two-sided), controlling for age and derived neuronal proportion (n = 47 biologically independent samples). Variation in H3K27ac at 4,162 peaks was identified as being associated with AD (red line, FDR < 0.05). b, Volcano plot showing the raw -log 10 (P) and log(fold change) values for differential H3K27ac at each entorhinal cortex H3K27ac peak (n = 47 biologically independent samples; red line, FDR < 0.05). Of the AD-associated peaks, 1,475 (35%, 95% CI: 34-37%) are hyperacetylated (higher H3K27ac) in AD and 2,687 (65%, 95% CI: 63-66%) are hypoacetylated (lower H3K27ac) in AD (exact binomial test, n = 4,162 peaks, P < 1.00 × 10
−50
).
a near-perfect correlation in AD-associated H3K27ac differences between models (Pearson's product-moment correlation, r = 1.00, P < 1.00 × 10 −50
; Supplementary Fig. 7 ). Given the neurodegeneration and neural cell changes associated with AD pathology, we also quantified the levels of transcripts associated with five major brain cell types (ENO2 for neurons, OLIG2 for oligodendrocytes, GFAP for astrocytes, CD68 for microglia, and CD34 for endothelial cells) in our samples (see Methods). As expected, expression of the neuronal gene ENO2 was correlated with the neuronal cell proportion estimates derived from DNA methylation data ( Supplementary  Fig. 8 ) and found to be reduced in AD samples (linear regression, n = 47 biologically independent samples, P = 0.023, β = − 0.54, Table 3 ). We also identified elevated expression of CD34 (n = 47 biologically independent samples, P = 0.047, β = 0.69, F 3,43 = 6.09), CD68 (n = 46 biologically independent samples, P = 0.012, β = 0.53, F 3,42 = 7.25), and GFAP (n = 47 biologically independent samples, P = 0.004, β = 0.75, F 3,43 = 3.27) in our AD cases (Supplementary Fig. 9 and Supplementary Table 3) , reflecting results from previous studies 19, 20 . Post hoc analyses of our AD-associated peaks using models controlling for levels of these five cell types showed that effects remained highly correlated with those from our original model (Pearson's product-moment correlations with results from models controlling for ENO2: r = 0.99, P < 1.00 × 10 −50
; OLIG2: r = 0.99, P < 1.00 × 10 −50
; GFAP: r = 0.99, P < 1.00 × 10 −50
; CD68: r = 0.99, P < 1.00 × 10 −50
; CD34: r = 0.99, P < 1.00 × 10
; and all cell markers combined: r = 0.98, P < 1.00 × 10 −50
), indicating that the AD-associated differences in H3K27ac were robust to cell-type heterogeneity ( Supplementary Fig. 10 ). Finally, for each sample we also calculated standard ENCODE ChIP-seq quality metrics (see Methods) and included these as post hoc covariates in our analyses; again, AD-association effect sizes remained highly correlated with those estimated from our original model (Pearson's productmoment correlation, r = 0.95, P < 1.00 × 10
). UCSC Genome Browser tracks showing H3K27ac levels in AD cases and controls, in addition to association statistics, across the genome can be accessed at https://epigenetics.essex.ac.uk/AD_ H3K27ac/. The ten top-ranked hyper-and hypoacetylated peaks associated with AD are shown in Table 1, with a complete list given in  Supplementary Table 4 (hyperacetylated peaks) and Supplementary  Table 5 (hypoacetylated peaks) . P values for sex, cell-type expression, and quality-metric-controlled models at each of the 4,162 differentially acetylated peaks are reported in Supplementary Tables 4  and 5 . Peaks were subsequently annotated to genes using an approach that takes into account the strength of proximal and distal DNA-binding events (see Methods). In total, differentially acetylated peaks were annotated to 4,039 genes (hyperacetylated peaks: 1,728 genes; hypoacetylated peaks: 2,528 genes). The most significant AD-associated hyperacetylated peak (chromosome (chr) 13: 112,101,248-112,102,698; P = 2.04 × 10 ; log(fold change) = 0.93) was annotated to both SOX1 and TEX29 on chromosome 13 ( Fig. 2 and Table 1 ). Of note, H3K27ac data from the Epigenomics Roadmap Consortium show that this region is characterized by brain-specific enhancer activity ( Supplementary Fig. 11 ). The most significant AD-associated hypoacetylated peak (chr7: 64,011,549-64,012,825; P = 1.66 × 10 ; log(fold change) = − 0.86) was located within intron 1 of ZNF680 on chromosome 7 (Fig. 3 , Table 1 , and Supplementary Fig. 11 ). Global clustering of samples by normalized read counts across all hyper-and hypoacetylated peaks (FDR < 0.05) indicated that, as expected, samples grouped primarily by disease status (Fig. 4) . AD-associated differentially acetylated peaks (FDR < 0.05) were significantly longer (Welsh two-sample t test, Articles Nature NeuroscieNce two-sided, P < 1.00 × 10
, average difference in length = 320.02 bp, 95% CI: 298-342 bp, t 4,340.5 = 28.70) and characterized by higher read-depths (in counts per million (CPM); P < 1.00 × 10 −50
, average difference in log(CPM) = 0.46, 95% CI: 0.42-0.50, t 4,463.7 = 24.33) than nonsignificant peaks ( Supplementary Fig. 12 ). Of note, within AD-associated peaks, hypoacetylated peaks were significantly longer (P = 5.66 × 10
−31
, average difference in length = 331.23 bp, 95% CI: 288-374 bp, t 3,303.8 = 15.17) and had higher read-depths (P = 2.69 × 10 −50
, average difference in log(CPM) = 0.45, 95% CI: 0.37-0.52, t 3,111.4 = 11.70) compared to hyperacetylated peaks. We used RSAT to identify enriched transcription-factor binding motifs located within AD-associated differentially acetylated peaks (see Methods), observing a significant enrichment of binding motifs for specificity protein 1 (Sp1; (binomial test, P < 1.00 × 10 −50
), a transcription factor that has been implicated in immune response, apoptosis, and chromatin remodeling, amongst AD hyperacetylated peaks (FDR < 0.05). Of note, previous publications have reported dysregulated expression of Sp1 and its colocalization with neurofibrillary tangles in AD 21, 22 . Differential H3K27ac is observed in regulatory regions annotated to genes previously implicated in both tau and amyloid neuropathology. One of the top-ranked AD-associated hyperacetylated peaks is located proximal to the gene encoding microtubule-associated protein tau (MAPT; chr17: 43,925,717-43,927,482; P = 7.01 × 10 ; log(fold change) = 0.71; Table 1 ), which is widely expressed in the nervous system, where it promotes microtubule assembly and stability. Tau is believed to play a key role in AD neuropathology, with hyperphosphorylation of the tau protein precipitating the neurofibrillary tangles associated with the pathogenesis of AD 23, 24 . Closer inspection of the region around this AD-associated peak highlighted an extended cluster of six hyperacetylated H3K27ac peaks (FDR < 0.05) spanning 36 kb (chr17: 43,925,717-43,961,546) located within a MAPT antisense transcript (MAPT_AS1) ~10 kb upstream of the MAPT transcription start site (Fig. 5 and Supplementary Table 6 ). H3K27ac ChIP-seq data from the NIH Epigenomics Roadmap Consortium show that this region is characterized by CNS-related H3K27ac signatures (Fig. 5) , and ChromHMM 25 identifies the region as an active chromatin domain in brain, comprised of enhancers and blocks of weak transcription ( Supplementary Fig. 13 ). Strikingly, AD-associated differentially acetylated peaks were also found in the vicinity of other genes known to play a direct mechanistic role in AD. We identified a significantly hypoacetylated peak (chr21: 27,160,993-27,161,475; P = 3.94 × 10 −4 ; log(fold change) = − 0.72) on chromosome 21, located ~100 kb downstream of the amyloid precursor protein gene (APP), which encodes the precursor molecule to Aβ , the main component of amyloid plaques [26] [27] [28] ( Supplementary Fig. 14) . We also identified significant hyperacetylation in the vicinity of the presenilin genes PSEN1 and PSEN2, which encode integral components of the gamma secretase complex and play a key role in generation of Aβ from APP 29 . In PSEN1, we found significantly elevated H3K27ac across a peak within intron 6 (chr14: 73,656,445-73,656,860; P = 3.44 × 10 ; log(fold change) = 0.68; Supplementary Fig. 15 ). In PSEN2 we identified consistent hyperacetylation in AD cases across nine H3K27ac peaks (FDR < 0.05) spanning a ~57-kb region upstream of the transcription start-site (chr1: 226,957,424-227,014,019; Fig. 6 , Supplementary Fig. 13 , and Supplementary Table 7 ). Of note, highly penetrant mutations in APP, PSEN1, and PSEN2 are associated with familial forms of early-onset AD 30 . We used a hypergeometric test (one-sided) to confirm a significant enrichment of AD-associated differential acetylation associated with (i) familial AD genes (APP, PSEN1, PSEN2): 11 FDR-significant peaks from a total of 163 annotated peaks, P = 0.001; (ii) the MAPT locus: six FDR-significant peaks from a total of 36 annotated peaks, P = 1.54 × 10 ; and (iii) all four AD pathology genes combined: 17 FDR-significant peaks from a total of 199 annotated peaks, P = 4.05 × 10 . The identification of altered regulation of these loci in late-onset sporadic AD brain further supports a key role for altered amyloid processing in the onset of neuropathology.
Genetic risk for AD is enriched in entorhinal cortex H3K27ac peaks, with specific differentially acetylated peaks overlapping known AD GWAS regions. Using the AD GWAS meta-analysis results from Lambert and colleagues 7 , we performed linkage-disequilibrium (LD) score regression to quantify the proportion of SNP showing weighted mean AD (n = 24 biologically independent samples) and control (n = 23 biologically independent samples) ChIP-seq coverage per million reads in addition to an overlay track highlighting the acetylation differences. (a) The most significant AD-associated hyperacetylated peak is characterized by a consistent increase in H3K27ac in patients (quasi-likelihood F test, two-sided, P = 2.04 × 10 −8 , FDR = 0.002, log(fold change) = 0.93). The center line of the boxplot shows the median, the outer hinges correspond to the 25th and 75th percentiles, respectively, and the whiskers extend to the most extreme observed value within 1.5× the interquartile range (IQR) from the two hinges. (b) This peak is located on chromosome 13 and annotated to both SOX1 and TEX29. Also shown is the location of all entorhinal cortex H3K27ac peaks in this region, hyper-and hypoacetylated peaks (FDR < 0.05), as well as the -log 10 (P) value and log(fold change) of normalized read count differences for each peak, calculated using a quasi-likelihood F test. UCSC gene, data from UCSC Genome Browser. 'FDR neg' and 'FDR pos' indicate hypo-and hyperacetylated peaks, respectively, in AD vs. control at FDR < 0.05.
heritability accounted for by variants colocalizing with the entorhinal cortex H3K27ac peaks identified in this study (see Methods). Of the total heritability across all SNPs derived from stage 1 of the GWAS meta-analysis results (h 2 = 0.0789), a large proportion (38.3%, h 2 = 0.0302; 95% CI: 0.0126-0.0478) was accounted for by variants within H3K27ac peaks, representing a significant enrichment (enrichment = 1.10; 95% CI: 1.05-1.15; Supplementary Table 8 ) and indicating that AD risk alleles were preferentially located in regions of regulatory and enhancer function in the brain. We next identified instances of overlap between AD-associated differential H3K27ac and genomic regions harboring risk variants. Briefly, we defined LD blocks around the genome-wide significant (P < 5.0 × 10 −8 ) GWAS variants identified by the stage 1 meta-analysis by Lambert and colleagues 7 (Supplementary Table 9 ), which contained a total of 292 overlapping entorhinal cortex H2K27ac peaks (see Methods). Two of the 11 GWAS LD blocks contained significant (FDR < 0.05) AD-associated H3K27ac peaks, although there was no overall enrichment of AD-associated differential acetylation at the 292 peaks (Wilcoxon rank-sum test with continuity correction, n = 182,065 peaks, P = 0.364, W = 27,354,000). Two peaks of AD-associated hyperacetylation were located within a GWAS region on chromosome 1, mapping to the gene body of CR1 (chr1: 207,753,457-207,753,813; P = 1.15 × 10 ; log(fold change) = 0.56; Supplementary  Fig. 16 ). CR1 encodes a transmembrane glycoprotein expressed in microglia with a role in the innate immune system, promoting phagocytosis of immune complexes and cellular debris in addition to Aβ [31] [32] [33] . Two other AD-associated differentially acetylated peaks were located within a GWAS region on chromosome 19, including a hyperacetylated peak (chr19: 45,394,441-45,395,396; P = 2.13 × 10 ; log(fold change) = 0.48) mapping to the gene body of TOMM40 in the immediate vicinity of APOE (Supplementary Fig. 17 ). Another H3K27ac peak in this LD block was significantly hypoacetylated in AD (chr19: 45,639,588-45,641,733; P = 7.65 × 10 ; log(fold change) = − 0.33), mapping to intron 1 of PPP1R37.
AD-associated differentially acetylated peaks are enriched for functional processes related to neuropathology. We next calculated statistical enrichments for ontological annotations amongst our AD-associated peaks (see Methods), interrogating gene ontologies for molecular function and biological processes, as well as for human diseases (hypergeometric test; see Supplementary Table 10 and Supplementary Fig. 18 , with a full list of significant ontologies in Supplementary Tables 11-16 ). Multiple ontological categories associated with AD progression and pathology were identified as being enriched (FDR < 0.05) amongst hyperacetylated peaks, including lipoprotein-particle binding 6, 34 (P = 1.10 × 10
), Aβ metabolic process 23 (P = 4.94 × 10 ; a form of frontotemporal dementia also characterized by tau pathology) 24, 37 . Amongst hypoacetylated peaks, we observed an enrichment of categories related to neurotransmitter functions, including GABA-receptor activity 38 (P = 2.70 × 10
), as well as categories related to neuronal transmission and synapses, such as protein location to synapse (P = 7.86 × 10
−9
). Because the observed enrichment for functional processes related to neuropathology might reflect underlying cellular heterogeneity between samples, we repeated these analyses using only peaks that were significantly differentially acetylated (FDR < 0.05) in our model controlling for all five neural cell types. Our sensitivity analyses confirmed that most AD-related pathway enrichments were robust to cellular heterogeneity, including lipoprotein-particle binding (P = 4.36 × 10 ). Although there was some overlap between the genes in each pathway (Supplementary Table 10 ) and the ontological categories we identify are not totally independent these results indicate a striking enrichment of AD-related pathways in both hyper-and hypoacetylated regions. , FDR = 0.002) is characterized by a consistent decrease in H3K27ac in cases (log(fold change) = − 0.86). The center line of the boxplot shows the median, the outer hinges correspond to the 25th and 75th percentiles, respectively, and the whiskers extend to the most extreme observed value within 1.5× the IQR from the two hinges. (b) This peak is located in intron 1 of ZNF680 on chromosome 7. Also shown is the location of all entorhinal cortex H3K27ac peaks in this region, hyper-and hypoacetylated peaks (FDR < 0.05), as well as the -log 10 (P) value and log(fold change) of normalized read count differences for each peak calculated using a quasi-likelihood F test.
AD-associated variable
Supplementary Table 1 ). The expression of RGCC and PIM3, both located proximal to hyperacetylated peaks, was found to be significantly upregulated in AD cases (linear regression; RGCC: n = 94 biologically independent samples, P = 0.002, β = 0.44, F 3,90 = 12.09; PIM3: n = 95 biologically independent samples, P = 1.16 × 10 −4 , β = 0.56, F 3,91 = 24.78; Fig. 7) . Furthermore, the expression of GPR22 and KMO, both located proximal to hypoacetylated peaks, was found to be significantly downregulated in AD cases (GPR22: n = 94 biologically independent samples, P = 0.006, β = − 0.69, F 3,90 = 2.69; KMO: n = 60 biologically independent samples, P = 0.004, β = − 0.99, F 3,56 = 3.01; Fig. 7 ). Of note, the expression of these four transcripts was positively associated with levels of H3K27ac (i.e., higher H3K27ac was associated with a reduced Δ Ct value) across their proximal AD-associated differentially acetylated peaks in samples included in our ChIP-seq dataset (quasi-likelihood F test, twosided; RGCC: n = 47 biologically independent samples, P = 0.123, log(fold change) = − 0.22; PIM3: n = 47 biologically independent samples, P = 0.023, log(fold change) = − 0.35; GPR22: n = 46 biologically independent samples, P = 1.1 × 10
, log(fold change) = − 0.38; KMO: n = 33 biologically independent samples, P = 0.050, log(fold change) = − 0.15; Supplementary Fig. 19 ). Notably, previous studies have implicated dysregulation of RGCC 39 , GPR22 40 , and KMO 41 in AD. In contrast, ANKRD17 and ZNF680 were not found to be differentially expressed in AD cases (Supplementary Table 17) ; we note that H3K27ac enhancer domains are often located considerable distances from their target genes 42 , and effects on more distal transcripts cannot be excluded. We also quantified the expression of six genes-previously implicated in tau and amyloid pathology or from GWAS-that were annotated to differentially acetylated peaks (MAPT, PSEN1, PSEN2, APP, TOMM40, and CR1; Supplementary Table 18 ). We found significantly higher expression of PSEN1 (linear regression, n = 95 biologically independent samples, P = 0.001 , β = 0.44, F 3,91 = 4.70) and CR1 (n = 91 biologically independent samples, P = 0.001, β = 0.70, F 3,87 = 5.50) in AD cases (Fig. 7) , reflecting the hyperacetylated peaks observed in the vicinity of these genes, with the expression of both transcripts being robustly associated with levels of H3K27ac across their proximal AD-associated differentially acetylated peaks in samples included in our ChIP-seq dataset (quasi-likelihood F test, two-sided; PSEN1: n = 47 biologically independent samples, P = 0.011, log(fold change) = − 0.42; CR1: n = 45 biologically independent samples, peak 1: P = 0.002, log(fold change) = − 0.37; peak 2: P = 0.001, log(fold change) = − 
Fig. 4 | Clustering of AD and low-pathology control samples by
H3K27ac levels at differentially acetylated peaks. a, A heatmap, clustering samples (n = 47 biologically independent samples) by normalized read counts in all 1,475 significant AD hyperacetylated peaks (FDR < 0.05) generates three distinct groups: one comprised of controls only (group 1, n = 13 biologically independent samples), a pure group of cases (group 2, n = 20 biologically independent samples), and a mixed group containing both cases and controls (group 3, n = 14 biologically independent samples). Controls grouped together with cases in group 3 (n = 10 biologically independent samples) are characterized by significantly decreased neuronal proportion estimates, compared to those in the pure control group 1 (Welsh two sample t test, two-sided, P = 7.10 × 10
, mean reduction in estimated neuronal proportion = 15%, 95% CI: 7-23%, t 19.81 = 4.00). CETS, neuronal cell proportion estimate based on cell epigenotype-specific marks (see Methods). b, A heatmap, clustering samples by all 2,687 significant AD hypoacetylated peaks (FDR < 0.05), divides the samples into two main groups: group 1 (n = 17 biologically independent samples) is composed mainly of controls, whereas group 2 (n = 30 biologically independent samples) contains more cases than controls. Notably, controls classified into group 2 are characterized by lower neuronal proportion estimates than those in group 1 (Welsh two sample t test, two-sided, n = 23 biologically independent samples, P = 0.004, mean reduction in neuronal proportion = 14%, 95% CI: 5-23%, t 15.85 = 3.41). The clustering defined by hyper-or hypoacetylated peaks is not significantly associated with sex (n = 47 biologically independent samples; hyperacetylated cluster: chi-squared test, P = 0.763, χ 2 (2) = 0.54; hypoacetylated cluster: chi-squared test with Yates' continuity correction, P = 0.269, χ 2 (1) = 1.22) or age at death (n = 47 biologically independent samples; hyperacetylated cluster: linear regression, P = 0.827, F 2,44 = 0.19; hypoacetylated cluster: Welsh two-sample t test, twosided, P = 0.580, mean age difference = − 1.59 years, 95% CI: − 7.36 to 4.18 years, t 37.20 = − 0.56). 0.31; Supplementary Fig. 20 ). In contrast, the expression levels of MAPT (linear regression, n = 94 biologically independent samples, P = 0.844, β = − 0.02, F 3,90 = 18.09), PSEN2 (n = 88 biologically independent samples, P = 0.913, β = 0.01, F 3,84 = 0.64), APP (n = 95 biologically independent samples, P = 0.087, β = − 0.21, F 3,91 = 1.98), and TOMM40 (n = 93 biologically independent samples, P = 0.329, β = − 0.08, F 3,89 = 2.72) were not significantly different between AD cases and controls, nor were they associated with proximal levels of H3K27ac (Supplementary Table 18 ).
Integrative analysis of DNA and histone modifications reveals unique distributions of DNA modifications across regions of differential acetylation. Our previous work identified cortex-specific variation in DNA methylation (5mC) robustly associated with AD pathology 9, 10 . We were therefore interested in exploring the relationship between H3K27ac and both 5mC and another DNA modification-DNA hydroxymethylation (5hmC), which is enriched in the brain and believed to play an important role in neuronal function, learning, and memory 43, 44 -in our samples. Both modifications were profiled using DNA isolated from the same entorhinal cortex samples using oxidative bisulfite conversion in conjunction with the Illumina 450 K HumanMethylation array (450 K array; see Methods). Focusing on 450 K array sites within 1 kb of our H3K27ac peaks, we identified 268,477 probe-peak pairs (comprising 232,233 unique 450 K array probes and 62,714 (34.45% of total) unique H3K27ac peaks). Of these, 6,838 probes mapped to within 1 kb of an AD-associated differentially acetylated peak (FDR < 0.05; n = 1,649 unique peaks: 616 hyperacetylated, 1,033 hypoacetylated). First, we tested for differential 5mC and 5hmC associated with AD at these probes, controlling for age at death and cell-type proportion estimates. None of the differences in 5mC (minimum P = 2.47 × 10 ) were significant when correcting for multiple testing (n = 6,838 tests; P < 7.31 × 10 ), indicating that there was little direct overlap in AD-associated variation in H3K27ac and DNA modifications. Comparing effect sizes at these 6,838 peak-probe pairs identified no evidence for an overall correlation between AD-associated H3K27ac and 5mC differences (Pearson's product-moment correlation, r = 0.009, P = 0.443; Supplementary Fig. 21 ) with a small but significant negative correlation for 5hmC (Pearson's product-moment correlation, r = − 0.045, P = 1.63 × 10
; Supplementary Fig. 21 ). As expected, both DNA modifications were significantly lower in the vicinity of H3K27ac peaks compared to the genome-wide 450 K array background (Welsh two-sample t test, two-sided; 5mC: P < 1.00 × 10 −50
, average H3K27ac mark on 7 cell lines from ENCODE CRHR1  CRHR1  CRHR1  CRHR1  CRHR1  CRHR1  CRHR1  CRHR1  CRHR1  CRHR1  MAPT-AS1  SPPL2C   MAPT  MAPT  MAPT  MAPT  MAPT  MAPT  MAPT  MAPT  MAPT-IT1  MAPT  STH  KANSL1  KANSL1  KANSL1  KANSL1 Table 5) . a, For six of the nine peaks this increase in H3K27ac associated with AD is significant (FDR < 0.05). The center line of the boxplot shows the median, the outer hinges correspond to the 25th and 75th percentiles, respectively, and the whiskers extend to the most extreme observed value within 1.5× the IQR from the two hinges. b,c, The region is located ~10 kb upstream of MAPT and characterized by brain-specific H3K27ac profiles. , average beta difference = 0.16%, 95% CI: 0.13-0.19%, t 494,170 = 10.99; Supplementary Fig. 21 ), consistent with H3K27ac being localized at active enhancers and promoters.
We next explored the relationship between variable 5mC and H3K27ac in our samples, finding that data for 439 probe-peak pairs (corresponding to 419 unique 450 K array probes and 319 unique H3K27ac peaks) were significantly correlated (FDR < 0.05; Supplementary Table 19) ; 414 (94.31%) of the significant correlations were negative, with higher H3K27ac being associated with lower 5mC. Of note, 12 of the significant associations between H3K27ac and 5mC involved an AD-associated differentially acetylated peak (Supplementary Table 20 and Supplementary Fig. 22 ). Notably, we identified an AD-associated differentially acetylated peak (chr4: 1,044,452-1,044,737, quasi-likelihood F test, two-sided, P = 0.001, log(fold change) = 0.83) annotated to FGFRL1 and RNF212 at which H3K27ac correlated with 5mC at three specific 450 K array probes (Pearson's product-moment correlation, n = 42 biologically independent samples; cg04016957, r = − 0.66, P = 1.66 × 10 ; cg21130718, r = − 0.70, P = 2.98 × 10
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Discussion
We quantified H3K27ac across the genome in postmortem entorhinal cortex tissue samples, identifying widespread AD-associated acetylomic variation. Strikingly, differentially acetylated peaks were identified in the vicinity of genes implicated in both tau and amyloid neuropathologies, as well as in genomic regions containing variants associated with sporadic late-onset AD. Partitioned heritability analysis highlighted a highly significant enrichment of AD risk variants in entorhinal cortex H3K27ac peak regions. Finally, targeted gene-expression analysis showed that variable H3K27ac was associated with transcriptional variation at proximal genes, including CR1, GPR22, KMO, PIM3, PSEN1, and RGCC. This is the first study of variable H3K27ac yet undertaken for AD; in addition to identifying molecular pathways associated with AD neuropathology, we introduce a framework for genome-wide studies of this modification in complex disease.
Given its close relationship with transcriptional activation, for example, via the mediation of transcription-factor binding, the identification of AD-associated variation in H3K27ac highlights potential novel regulatory genomic pathways involved in disease etiology. We found widespread alterations in H3K27ac associated with AD, including in the vicinity of several genes known to be directly involved in the progression of Aβ and tau pathology 23, 45 (APP, PSEN1, PSEN2, MAPT), supporting the notion that dysregulation of both pathways is involved in the onset of AD. Notably, although our study assessed brains from donors affected by sporadic lateonset AD, we identified widespread altered H3K27ac in the vicinity of genes implicated in familial early-onset AD. This indicates that these two forms of the disease may share common pathogenic pathways and mechanisms. Given that histone-acetylation modifiers are amongst the most promising target pharmacological treatments of AD 13, 46 , the identification of altered H3K27ac in AD is important, giving clues as to which genes and pathways may be involved.
Our study has a number of limitations that should be considered when interpreting these results. First, we undertook ChIP-seq using bulk entorhinal cortex samples comprising a mix of neuronal and non-neuronal cell types. This is an important limitation in epigenomic studies of a disease characterized by cortical neuronal loss. However, we were able to control, in part, for variation in neuronal proportions in our samples by (i) deriving neuronal proportion estimates for each sample using DNA methylation data generated Table 6 ). a, For nine of the 14 peaks this increase in H3K27ac associated with AD is significant (FDR < 0.05). The center line of the boxplot shows the median, the outer hinges correspond to the 25th and 75th percentiles, respectively, and the whiskers extend to the most extreme observed value within 1.5× the IQR from the two hinges. b,c, The region is located ~44 kb upstream of PSEN2 and characterized by predominantly brain-specific H3K27ac profiles. The boundaries of the significantly differentially acetylated peak region are highlighted in red.
on the same tissue samples 47 and (ii) quantifying the expression of levels of transcripts associated with five major brain cell types (ENO2 for neurons, OLIG2 for oligodendrocytes, GFAP for astrocytes, CD68 for microglia, and CD34 for endothelial cells) in our samples. Despite these efforts to control for cellular heterogeneity, however, it is plausible that we have not selected the most optimal cell-type-specific markers for this purpose, especially because certain markers reflect both the activity and abundance of specific cell types (for example, CD68 in microglia). Second, our cross-sectional analysis of postmortem brain tissue makes direct causal inference difficult, and it is likely that many of the changes in H3K27ac we observed resulted from the AD pathology itself. In this regard, however, it is noteworthy that we saw disease-associated H3K27ac in the vicinity of genes causally implicated in familial forms of AD and that we were able to show that genes annotated to specific differentially acetylated peaks showed disease-associated gene-expression differences in the same samples. Third, although our targeted gene expression analyses identified differences at a number of genes annotated to differentially acetylated peaks, we cannot make any conclusions about the relationship between H3K27ac and gene expression at a genome-wide level. Fourth, we have assessed a relatively small number of samples. In this light, it is notable that we identified substantial differences between AD cases and controls, with disease-associated regulatory variation in genes and functional pathways known to play a role in the onset and progression of neuropathology. The clear clustering between patients and controls at our differentially acetylated peaks suggests that, despite a complex and heterogeneous etiology, AD may be characterized by a common molecular pathology in the entorhinal cortex, reflecting neuropathological analyses. Furthermore, our differential gene-expression analyses of transcripts associated with selected differentially acetylated peaks highlighted consistent differences in an extended set of samples. Fifth, chromatin architecture and transcriptional regulation is influenced by a multitude of epigenetic mechanisms. Although profiling H3K27ac can provide relatively robust information about transcriptional activity, it represents only one of perhaps ~100 post-translational modifications occurring at more than 60 histone amino acid residues regulating genomic function. A recent study, for example, identified dysregulation of H4K16ac in AD brain 48 . Finally, we annotated genes to H3K27ac peaks by assigning genes to regulatory regions within 5 kb upstream and 1 kb downstream of the transcription start site (proximal), or up to 1,000 kb for distal interactions, although such an approach may not be optimal. Recent chromatin-conformation studies suggest that distal enhancers may not necessarily regulate the most proximal gene 49 ; although no detailed chromosomal conformational capture (Hi-C) data currently exist for adult human cortex, generation of these data will enable us to further interrogate the functional consequences of the AD-associated differences reported here.
In summary, we provide evidence for widespread acetylomic dysregulation in the entorhinal cortex in AD. Our data suggest that regulatory variation at multiple loci, including in the vicinity of several known AD risk genes-APP, CR1, MAPT, PSEN1, PSEN2, and TOMM40-is robustly associated with disease, supporting the notion of common molecular pathways in both familial and sporadic AD. In addition to identifying molecular pathways associated with AD neuropathology, we present a framework for genome-wide studies of histone modifications in complex disease, integrating our data with results obtained from GWAS as well as other epigenetic marks profiled on the same samples.
online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41593-018-0253-7. Shown for each gene is the relative expression (log 2 (fold ratio)) in AD cases (n = 67 biologically independent samples) and controls (n = 28 biologically independent samples). The center line of the boxplot shows the median, the outer hinges correspond to the 25th and 75th percentiles, respectively, and the whiskers extend to the most extreme observed value within 1.5× the IQR from the two hinges. For each of the genes shown, we identified a significant difference between groups in the direction predicted from our H3K27ac ChIP-seq data. The expression of RGCC, PIM3, PSEN1, and CR1, all located proximal to hyperacetylated peaks, was found to be significantly upregulated in AD cases (linear regression, RGCC: n = 94 biologically independent samples, P = 0.002, β = 0.44, 
Methods
Samples. Postmortem brain samples from 95 individuals, 67 with advanced AD neuropathology and 28 neuropathology-free brain samples, were provided by the MRC London Neurodegenerative Disease Brain Bank (https://www.kcl.ac.uk/ ioppn/depts/bcn/our-research/neurodegeneration/brain-bank.aspx). No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to, or larger than, those reported in previous brain ChIP-seq analyses 17, 48 . Ethical approval for the study was provided by the NHS South East London Research Ethics Committee (REC) 3. Subjects were approached in life for written consent for brain banking, and all tissue donations were collected and stored following legal and ethical guidelines (NHS reference number 08/MRE09/38; the HTA license number for the LBBND brain bank is 12293). Samples for this ChIP-seq study were selected from a larger collection of postmortem entorhinal cortex (Brodmann area (BA) 28/34) samples, based on Braak staging, a standardized measure of neurofibrillary tangle burden determined at autopsy 51 . We prioritized cases with high Braak staging and controls with lower Braak scores (Supplementary Table 1 ). All samples were dissected by trained specialists, snap-frozen and stored at − 80 °C. SNP array data from each donor generated using the Illumina Infinium HumanCore-24; SNP array was merged with HapMap Phase 3 data, and genetic principal components (PCs) were calculated with GCTA 52 to confirm the ethnicity of each sample as European (Supplementary Fig. 1) . A detailed list of demographic and sample data for each individual included in the final analyses is provided in Supplementary Table 1 .
Chromatin immunoprecipitation (ChIP).
Tissue from a subset of 27 individuals with advanced AD neuropathology and from 27 individuals with minimal neuropathology were selected for our ChIP-seq analyses. Samples were randomized at all experimental stages, with processing batches comprising an equal number of AD cases and controls. Samples were labeled with anonymized ID codes and processed in batches, blinding disease status from the experimenter/ analyst for individual samples. Chromatin immunoprecipitation was performed using the iDeal ChIP-Seq kit for Histones (Cat# C01010051, Diagenode, Seraing, Belgium) as detailed below, using the standard kit components unless otherwise stated. First, 30 mg of entorhinal cortex tissue was homogenized with a dounce homogenizer in 1 mL ice-cold phosphate buffered saline (PBS) buffer with protease inhibitor cocktail (PIC). The suspension was centrifuged at 4,000 rpm for 5 min at 4 °C, discarding the supernatant. The pellets were resuspended in 1 mL PBS containing 1% formaldehyde, rotating at room temperature (~20 °C) for 8 min. The cross-linking process was terminated by adding 100 μ L glycine solution, followed by 5 min of rotation. After 5 min of centrifugation at 4,000 rpm and 4 °C, the pellet was washed twice with ice-cold PBS (suspending the pellet in 1 mL PBS with PIC, centrifuging for 5 min at 4,000 rpm and 4 °C, and discarding the supernatant), then lysed in 10 mL ice-cold lysis buffers iL1 and iL2, sequentially (resuspending the pellet in 10 mL lysis buffer, mixing gently for 10 min at 4 °C, centrifuging for 5 min at 4,000 rpm and 4 °C, and discarding the supernatant). The cross-linked lysate was suspended in 1.8 mL shearing buffer iS1 containing PIC and sonicated in aliquots of 300 μ L for 10 cycles (30 s on/off each cycle) on a Bioruptor Pico (Diagenode, Seraing, Belgium). After shearing, samples were transferred to 1.5-mL microcentrifuge tubes and centrifuged at 14,000 rpm for 10 min, collecting the supernatant, which contained the soluble sheared chromatin with fragments of an average size range of 100-1,000 bp as visualized by agarose gel electrophoresis ( Supplementary Fig. 23) .
Immunoprecipitation was performed on the SX-8G IP-Star robot (Diagenode, Seraing, Belgium), following the manufacturer's protocol. All samples were immunoprecipitated with H3K27ac polyclonal antibody (Diagenode, Seraing, Belgium; Cat #C15410196, lot number: A1723-0041D). This antibody has been validated for ChIP-seq applications (validation data from Diagenode available at https://www.diagenode.com/en/p/h3k27ac-polyclonal-antibody-premium-50-mg-18-ml). In addition, a randomly selected subgroup of 12 samples (6 cases and 6 controls) was immunoprecipitated with rabbit IgG antibody (iDeal ChIP-seq kit) as negative control. We first mixed 1-1.5 μ L of H3K27ac or IgG antibody with 98.5-99 μ L ChIP buffer iC1, 0.5 μ L PIC, and 4 μ L of 5% bovine serum albumin (BSA), which was incubated with magnetic beads for 3 h at 4 °C. Next the antibody conjugate was added to 180 μ L chromatin for overnight (15 h) immunoprecipitation at 4 °C in an immunoprecipitation mix also containing 20 μ L ChIP buffer iC1, 1 μ L PIC, and 4 μ L of 5% BSA. After immunoprecipitation, the beads were resuspended in in 100 μ L elution buffer iE1, to which 4 μ L elution buffer iE2 was added. Cross-link reversal was performed on a PCR thermoblock for 4 h at 65 °C. DNA was extracted using Micro ChIP DiaPure columns (Diagenode, Cat No C03040001, Seraing, Belgium) according to the manufacturer's protocol, eluting the DNA from the column matrix in 30 μ L DNA elution buffer (MicroChIP DiaPure columns; Diagenode, Cat #C03040001, Denville, NJ, USA). Quantitative PCR, using 1% input DNA, was used to confirm specific enrichment of H3K27ac at positive-control genes (IEF4A2 and GAPDH) but not at negativecontrol genes (MBex2 and TSH2b; all primers were provided by Diagenode).
Illumina short-read sequencing. Libraries were prepared using the MicroPlex Library Preparation kit v2 (Diagenode, Cat #C05010013, Seraing, Belgium) on a SX-8G IP-Star robot according to the manufacturer's protocol. DNA concentrations were measured with Qubit dsDNA HS Assay Kits (Invitrogen, Cat# Q32851, Carlsbad, CA, USA) on the Qubit 2.0 Fluorometer (Invitrogen), and library fragment profiles were generated on the Agilent 2100 BioAnalyzer using Agilent High Sensitivity DNA kits (Agilent Technologies, Cat# 5067-4626, Santa Clara, CA, USA). Following our stringent quality-control filtering, 7 samples were excluded from sequencing based on poor qPCR results after immunoprecipitation or low library concentration. The remaining 47 samples (from 24 cases and 23 controls) were sequenced on an Illumina HiSeq-2500 using single-end sequencing and a read length of 50 bp. ChIP-seq data are available to download from GEO (accession number GSE102538).
Data preprocessing and quality control. Global sample anomalies were ruled out using fastqc 53 summary measures. All fastq files were aligned to the Homo sapiens reference genome (hg19, Broad Institute) using Bowtie 54 . The output SAM files were converted to binary (BAM) format. All BAM files were sorted and indexed using samtools 55 . PCR duplicates were removed using Picard (http://broadinstitute. github.io/picard/). Samtools was used to additionally remove nonuniquely mapped reads, as well as reads with a sequencing quality score q < 30. Final read counts after QC for all 47 samples are shown in Supplementary Fig. 2 . On average, we obtained 30,032,623 reads per sample (s.d. = 10,638,091; range = 10,910,000-53,770,000), and individual read counts did not associate with disease status (Welsh two-sample t test, two-sided, n = 47 biologically independent samples, P = 0.93, average read count difference: 260,673, 95% CI: − 6,602,319-6,080,972, t 43.85 = − 0.08). For each sample we also calculated standard ENCODE ChIP-seq quality metrics (see https://genome.ucsc.edu/ENCODE/qualityMetrics.html#definitions): uniquely mappable reads (UMR), normalized stand cross-correlation (NSC), relative strand cross-correlation (RSC) and nonredundancy fraction (NrF), as well as the percentage of reads in peaks. These quality metrics were included as post hoc covariates in our analyses.
Peak calling and read counts. All filtered BAM files were merged into one grouped file and converted to tagAlign format using bedtools 56 . Peaks were called on this merged file using MACS2 57 , keeping all duplicates, as duplicates were removed from each sample previously and any remaining duplicates would result from the same read occurring in more than one sample. From the resulting peaks, those located in unmapped contigs and mitochondrial DNA were filtered out, as were peaks that did not meet a significance threshold of P < 1.00 × 10 −7 for peak calling. The bed file of peaks was converted to gff format using awk and R, and reads for each individual sample were generated using HTSeq 58 . Final filtering was performed using the Bioconductor package EdgeR 59 , excluding peaks with > 2 samples showing at least 1 read per million, resulting in a total of 182,065 peaks to be tested. Principal components analysis (PCA) in R using DESeq2 60 confirmed that the epigenetically predicted gender was identical to the recorded one ( Supplementary Fig. 6 ), with load on the first two principal components not related to disease status. Analysis scripts related to this project are available to download from https://epigenetics.essex.ac.uk/AD_H3K27ac/.
Peak validation. We validated the 182,065 union peaks in two ways. First, we obtained the locations of H3K27ac peaks called in the cortex (BA9) and cerebellum from a recent paper by Sun and colleagues 17 . Second, we downloaded H3K27ac profiles produced by the NIH Roadmap Epigenomics Consortium 18 from the GEO for multiple cell/tissue types, including several brain regions (mid-frontal lobe (GSM773015), inferior temporal gyrus (GSM772995), middle hippocampus (GSM773020), substantia nigra (GSM997258), cingulate gyrus (GSM773011), H1-derived neuronal progenitor cells (HDNPs, GSM753429), lung (GSM906395), liver (GSM1112808), and skeletal muscle (GSM916064). The downloaded files were in bed format, on which we performed peak calling using MACS2 and the same specifications as described for our own samples, discounting any duplicate reads. We calculated the overlap between each peak set and our peaks by quantifying the percentage of peaks from the external sample overlapping our peaks using the Bioconductor package GenomicRanges 61 . In addition, using the 182,065 entorhinal cortex (EC) peak regions identified in this study, we generated read counts on the raw H3K27ac data from cerebellum, prefrontal cortex (PFC), and temporal cortex (TC) published by Sun et al. 17 . Counts per million (CPM) at all peaks were scaled and centered before principal components analysis.
Differential peak calling. We used the quasi-likelihood F test 62 in EdgeR 59 to analyze peak differences between AD cases and controls, allowing us to correct for potential confounders in the analysis of differential peaks. Our analyses accounted for additional phenotypic variation across the samples, including age at death and neuronal proportion estimates (based on DNA methylation profiles from the Illumina 450 K HumanMethylation Array) from the same samples, which were calculated using the CETS R package 47 . We imputed the median CETS estimate for one individual with missing DNA methylation data. Age at death and CETS estimates were converted to five-level factors using the R function cut(), specifying five breaks before being included as covariates in the EdgeR differential peak calling method. This function divides a numerical variable into five bins of equal length, determined by the range of the variable. The distribution of the age and CETS variables (including the imputed individual) with the respective bins of the factor variables are shown in Supplementary Fig. 5 . We next calculated normalization factors based on sample-specific library compositions and estimated both sample and peak-specific dispersions, specifically for a generalized linear model controlling for factorized CETS estimates and age at death. The quasilikelihood F test was conducted after fitting a quasi-likelihood model 62 using the glmQLFit() and glmQLFTest() functions. Effect sizes are reported as log(fold change), a standard measure for quantifying sequencing read-count differences between different conditions. log(fold change) refers to the log 2 -transformed ratio of normalized read counts between cases and controls, with positive values indicating higher normalized read counts in AD samples. As further sensitivity analyses, we repeated the differential peak calling model, covarying additionally for (i) sex, (ii) expression of cell-type-specific marker genes for the five major brain cell-types (CD34, CD68, ENO2, GFAP, and OLIG2; see "Gene expression analyses") individually and combined, and (iii) five ChIP-seq quality metrics (UMR, RSC, NSC, NrF and percent reads in peaks -see "Data preprocessing and quality control"). P values in each of the additional control models at all 4,162 differentially acetylated peaks from our main model are reported in Supplementary Tables 4 and 5. The bedtools program genomecov was used to generate coverage value, scaled by library size and the number of samples per group, for each sample. These were then joined using unionbedg and summed using a Perl script to produce a weighted mean for each variable-sized interval defined by read overlaps and used to generate UCSC genome browser tracks (accessible at https:// epigenetics.essex.ac.uk/AD_H3K27ac/).
Genomic annotation and enrichment analyses. Peaks were annotated to genes using the Genomic Region Enrichment and Annotation Tools (GREAT) 50 , using the basal plus extension option and assigning genes to regulatory regions within 5 kb upstream and 1 kb downstream of the transcription start site (proximal) or up to 1,000 kb for distal interactions. In addition, we performed enrichment analyses calculating statistical enrichments for ontological annotation (gene ontologies for molecular function, biological processes 63 , and human diseases 64 ). Functional enrichment analyses were conducted for significantly hyper-and hypoacetylated peaks (FDR < 0.05) separately, using the basal plus extension option. Significance in the enrichment test was based on a hypergeometric test of genes annotated to the test set (hyper-/ hypoacetylated peaks) compared to the background set of genes annotated to all 182,065 peaks called across all samples. Results presented in Supplementary Fig. 18 are restricted to the top five nonredundant enrichments (separated by at least two nodes in the local directed acyclic graph visualizing the hierarchy of enriched terms from a single ontology) associated with at least three genes in the test set for the ontology categories biological process, molecular function, and disease ontology, and we show full enrichments across all categories in Supplementary Tables 11-16 . Enrichments for familial AD and AD pathology genes were calculated using a one-tailed hypergeometric test.
Motif enrichment analysis.
Motif analysis was performed using the Regulatory Sequence Analysis Tools suite (RSAT) 65, 66 , available at http://rsat.sb-roscoff.fr. Peak sequences were reduced to 1,500 bp on each side of the peak center, and motif discovery was conducted on 6mer and 7mer oligonucleotides, comparing the statistically enriched sequences with known transcription factor motifs from JASPAR 67 (core nonredundant vertebrates) and Homer 68 (Human TF motifs). Enrichments were computed using a binomial test, relative to the background peak sequences (n = 182,065 peaks) for significantly hyper-and hypoacetylated peaks (FDR < 0.05).
Integration of H3K27ac
ChIP-seq data with results from AD GWAS. The summary statistics for the stage 1 GWAS from Lambert and colleagues 7 were downloaded from http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_ download.php. These results were clumped (p1 = 1 × 10
, r2 = 0.1, window = 3,000 kb) using plink 69 , which collapses multiple correlated signals (due to LD) into regions that contain independent signals. LD relationships were inferred from a reference genotype dataset (Phase 1) from another study 70 . Neighboring regions located within 250 kb of each other on the same chromosome were subsequently merged. After clumping, each region was assigned the minimum P value for all SNPs contained in the region (from Lambert et al.), and regions were then filtered to the genome-wide significance threshold (P < 5.0 × 10 −8 ). This yielded 11 LD blocks for the genome-wide significant findings from Lambert et al., which were then overlapped with our AD-associated differentially acetylated peaks using the Bioconductor package GenomicRanges 61 .
To estimate the proportion of AD heritability attributable to H3K27ac peaks in adult brain, we performed partitioned heritability analysis using the LD Score regression software (https://github.com/bulik/ldsc) 71, 72 . LD scores were generated based on custom annotations derived from our ChIP-seq data and 1,000 Genomes reference data (downloaded alongside the software from https://data. broadinstitute.org/alkesgroup/LDSCORE/). Genetic variants were annotated to our ChIP-seq peaks, and heritability statistics were calculated using the publicly available GWAS results from Lambert et al. 7 . Enrichment statistics were calculated as the proportion of heritably divided by the proportion of SNPs for variants annotated to H3K27ac peaks.
Gene expression analysis. We homogenized 30-50 mg of frozen entorhinal cortex tissue from 95 individuals (67 high neuropathology; 28 low neuropathology) with Qiazol (Qiagen, Valencia, CA, USA), per the manufacturer's instructions, before running it through a QIAshredder (Qiagen, Valencia, CA, USA). Total RNA was extracted using the Qiagen RNeasy column-purification system and treated with DNase I. The Agilent 2200 TapeStation was used to check the quality and concentration of the extracted RNA samples. Complementary DNA (cDNA) was reverse transcribed using the Invitrogen VILO cDNA synthesis kit (Life Technologies) in 20-μ L reactions according to the manufacturer's instructions. After stringent QC, quantitative RT-PCR was performed in duplicate using the QuantStudio 12 K Flex (Applied Biosystems) in conjunction with the TaqMan low-density array (TLDA) platform using off-the-shelf preoptimized assays targeting (i) genes located proximal to top-ranked AD-associated H3K27ac peaks (ANKRD17, GPR22, KMO, RGCC, PIM3, and ZNF680), (ii) additional genes previously implicated in AD etiology and/or neuropathology and also annotated to significant differentially acetylated peaks (APP, CR1, MAPT, PSEN1, PSEN2, and TOMM40), (iii) genes expressed in the major brain cell types to control for celltype heterogeneity (ENO2 for neurons, OLIG2 for oligodendrocytes, GFAP for astrocytes, CD68 for microglia, and CD34 for endothelial cells), and (iv) five housekeeping genes (ACTB, EIF4A2, GAPDH, SF3A1, and UBC) identified as being most stably expressed in the brain using GeNORM (Primer Design, Southampton, UK). A full list of qPCR assays used is given in Supplementary Table  21 . PCR cycling conditions were 50 °C for 2 min, 94.5 °C for 10 min, and 45 cycles of 97 °C for 15 s and 60 °C for 1 min. We undertook stringent QC of raw qPCR data, removing samples where there was high variability between duplicates (Ct > 0.5). The abundance of each test gene was determined by the comparative Ct method 73 , expressed relative to the geometric mean of the five housekeeping genes quantified in parallel. Data were log 2 -transformed to ensure normal distribution and presented as a fold-difference in expression of AD cases relative to controls. Associations of gene expression were assessed by linear regression of Δ Ct against disease status, incorporating experimental variables (RNA isolation batch, RIN score) as covariates. We tested for an association between H3K27ac and gene expression using EdgeR as described above, including RNA isolation batch and RIN score as covariates.
Integrative analysis with DNA methylation and hydroxymethylation. DNA methylation and hydroxymethylation data was available (A.R.S., unpublished data) from entorhinal cortex DNA for 42 of the samples profiled using ChIP-seq in this study. DNA methylation and hydroxymethylation profiles were generated on the Illumina Infinium HumanMethylation450 BeadChip (Illumina Inc., CA, USA; '450 K array') using the TrueMethyl Array kit (Cambridge Epigenetix, Cambridge, UK). Profiles for both modifications were preprocessed, normalized, and filtered according to a stringent, standardized quality-control pipeline, as described previously 43 using the wateRmelon 74 package in R. We identified probes on the array within 1 kb of differentially acetylated peaks (FDR < 0.05) using the Bioconductor package GenomicRanges 61 , resulting in 268,477 peakprobe pairs (comprising 232,233 unique 450 K array probes and 62,714 (34.45% of total) unique H3K27ac peaks). Of these, 1,649 of the 4,162 FDR-significant differentially acetylated peaks were located within 1 kb of at least one CpG probe on the array, with a total of 6,838 probes mapping to the 1 kb neighborhood of these 1,649 peaks. For each CpG-peak pair, we correlated the log(fold change) in H3K27ac between AD cases and controls to the difference in DNA methylation or hydroxymethylation between AD cases and controls estimated from a linear model controlling for the same covariates as in the differential acetylation analysis. We examined patterns of DNA methylation and hydroxymethylation across probes in the vicinity of AD hyper-and hypoacetylated peaks, as well as those in vicinity of all background peaks and the whole microarray background using Welsh two-sample t tests. Finally, we analyzed the correlation of acetylation and DNA methylation at all peak-probe pairs using a Pearson's product-moment correlation between H3K27ac counts per million and DNA methylation (normalized betas).
Statistical analysis.
For the ChIP-seq analysis we used the quasi-likelihood F test 62 in EdgeR 59 . Our analyses accounted for additional phenotypic variation across the samples, including age at death and neuronal proportion estimates based on DNA methylation profiles from the 450 K array from the same samples, which were calculated using the CETS R package 47 . Peaks were considered differentially acetylated at FDR < 0.05 (controlled by Benjamini-Hochberg for n = 182,065 tests). ChIP-seq data is summarized as read counts per peak and sample. EdgeR assumes a negative binomial distribution, which is the most appropriate distribution for overdispersed count data, such as sequencing read counts in features. The data distribution at each of the 182,065 peaks was not formally tested. Associations of gene expression were assessed by linear regression of Δ Ct against disease status, incorporating experimental variables (RNA isolation batch, RIN score) as covariates. We tested for an association between H3K27ac and gene expression using EdgeR as described above, including RNA isolation batch and RIN score as covariates. Given that the statistical software R cannot report arbitrarily small P values due to computational memory constraints, we report P < 1.00 × 10 −50
whenever the software output showed P = 0 or a P value less than 1.00 × 10 All studies must disclose on these points even when the disclosure is negative.
Sample size
In total we profiled H3K27ac in dissected entorhinal cortex from 24 independent Alzheimer's disease (AD) samples and 23 independent control samples. This cohort represents a unique sample of brain tissues; we used all available samples at the time, representing to our knowledge the largest set of entorhinal cortex samples profiled for any histone modification as well as the largest set of samples profiled for H3K27ac in Alzheimer's disease. Despite a conservative FDR corrected significance threshold we obtained > 4,000 significant differentially acetylated peaks, including in loci known to be involved in AD pathology.
We used an extended set of dissected entorhinal cortex tissue from 95 individuals (67 AD samples and 28 control samples) for targeted qPCR gene expression analysis. This enabled us to explore the relationship between variable H3K27ac and gene expression in a matched set of samples, and confirm downstream expression changes in an extended replication dataset.
Data exclusions ChIP-seq samples were excluded if they did not pass stringent chromatin immunoprecipitation (ChIP) quality control experiments. 7 samples were excluded due to poor qPCR results after immunoprecipitation. This is described in the Online Methods "Illumina short-read sequencing".
Samples from gene expression RT-PCR analyses were excluded if they showed high variability between duplicates (Ct > 0.5). This is described in detail in the Online Methods "Gene expression analysis".
Replication
We validated our peak set in two ways. First, we obtained the locations of H3K27ac peaks called in the cortex (BA9) and cerebellum from a recent paper by Sun et al, 2016 (Cell. 2016 Nov 17;167(5):1385-1397). Second, we downloaded H3K27ac profiles produced by the NIH Roadmap Epigenomics Consortium from the Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo) for multiple cell-/tissuetypes including several brain regions (mid frontal lobe (GSM773015), inferior temporal gyrus (GSM772995), middle hippocampus (GSM773020), substantia nigra (GSM997258), cingulate gyrus (GSM773011), H1-derived neuronal progenitor cells (HDNPs, GSM753429), lung (GSM906395), liver (GSM1112808) and skeletal muscle (GSM916064)). All attempts at peak validation using these approaches were successful, indicating that our H3K27ac data reflected those from previous cortical analyses.
We also tested for gene expression differences at loci annotated to top-ranked differentially acetylated peaks. The sample used for differential expression analysis included an additional 48 individuals. As described in the results we were able to demonstrate a relationship between variable H3K27ac and gene expression for several key loci and confirmed differential expression at genes annotated to differentially acetylated peaks. Differential expression was shown for CR1, GPR22, KMO, PIM3, PSEN1 and RGCC, but not for MAPT, PSEN2, ANKRD17, TOMM40, APP or ZNF680.
Randomization Samples were randomized at all experimental stages, with processing batches comprising an equal number of AD cases and controls.
Blinding
Samples were labeled with anonymized ID codes and processed in batches, blinding disease status from the experimenter/analyst for individual samples.
Reporting for specific materials, systems and methods
